Fernando Moreno

3.1k total citations
69 papers, 556 citations indexed

About

Fernando Moreno is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Fernando Moreno has authored 69 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 22 papers in Cancer Research and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Fernando Moreno's work include Advanced Breast Cancer Therapies (16 papers), Historical Art and Architecture Studies (11 papers) and Breast Cancer Treatment Studies (11 papers). Fernando Moreno is often cited by papers focused on Advanced Breast Cancer Therapies (16 papers), Historical Art and Architecture Studies (11 papers) and Breast Cancer Treatment Studies (11 papers). Fernando Moreno collaborates with scholars based in Spain, United States and Ireland. Fernando Moreno's co-authors include José Á. García-Sáenz, Miguel Martín, Eduardo Díaz‐Rubio, Sara López‐Tarruella, Antonio Casado, Javier Puente, Enrique Grande, Jesús García-Donás, Carmen Guillén‐Ponce and Julián Sanz‐Ortega and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Fernando Moreno

56 papers receiving 540 citations

Peers

Countries citing papers authored by Fernando Moreno

Since Specialization

Citations

This map shows the geographic impact of Fernando Moreno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Moreno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Moreno more than expected).

Fields of papers citing papers by Fernando Moreno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Moreno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Moreno. The network helps show where Fernando Moreno may publish in the future.

Co-authorship network of co-authors of Fernando Moreno

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Moreno. A scholar is included among the top collaborators of Fernando Moreno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Moreno. Fernando Moreno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Correlation of HER2 levels expression through HER2 mRNA PCR vs immunohistochemistry (IHC) in hormone receptor positive (HR+)/HER2 negative (HER2−) early breast cancer 2025 ·Clinical & Translational Oncology ·(unknown), (unknown), Michael Amann, (unknown), Beatriz González, Alejandro Pascual, Cristina Díaz del Arco, Vanesa García‐Barberán, (unknown), (unknown), José Á. García-Sáenz, Fernando Moreno	0
2	A retrospective study of do-not-do practice recommendations in metastatic breast cancer in Spain 2024 ·Revista de Senología y Patología Mamaria ·(unknown), (unknown), Fernando Moreno, Pura Ballester, (unknown), (unknown), (unknown), José Joaquín Mira	0
3	Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort 2024 ·Breast Cancer Research and Treatment ·Rodrigo Sánchez-Bayona, (unknown), (unknown), Ana Sánchez, (unknown), Isabel Echavarría, Fernando Moreno, Pablo Tolosa, (unknown), (unknown), (unknown), (unknown), Ainhoa Madariaga, Sara López‐Tarruella, Luís Manso, Coralia Bueno, José Á. García-Sáenz, Eva Ciruelos, Miguel Martín	7
4	Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study 2023 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jesús Fuentes‐Antrás, (unknown), (unknown), Fernando Moreno, José Á. García-Sáenz	1
5	Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial 2023 ·Therapeutic Advances in Medical Oncology ·Ariadna Tibau, María Teresa Martínez, Manuel Ramos, Luis de la Cruz‐Merino, Ana Santaballa, Miriam O’Connor, Noelia Martínez-Jáñez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de la Haba-Rodríguez, Pedro Sánchez‐Rovira, (unknown), Coralia Bueno, Catherine M. Kelly, Maribel Casas, Susana Bezares, (unknown), Joan Albanell	8
6	La Inmaculada carmelitana. Concreciones del tipo iconográfico en Europa y Nueva España 2020 ·Goya: Revista de arte ·Fernando Moreno	1
7	LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC) 2020 ·Annals of Oncology ·Joan Albanell, (unknown), (unknown), (unknown), Luis de la Cruz‐Merino, Ana Santaballa Bertrán, Noelia Martínez-Jáñez, Fernando Moreno, (unknown), Juan Antonio Virizuela Echaburu, Juan de la Haba-Rodríguez, Pedro Sánchez‐Rovira, Lucía González‐Cortijo, Mireia Margelí Vila, Alfonso Sánchez Muñoz, (unknown), María Isabel Casas, (unknown), (unknown)	2
8	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain 2020 ·The Oncologist ·Miguel Martín, Ángel Guerrero‐Zotano, Á. Montero, Carlos Jara, (unknown), Federico Rojo, Fernando Moreno, José Á. García-Sáenz, (unknown), José Ignacio Chacón, Josefina Cruz, (unknown), Luis de la Cruz‐Merino, M. Algara, Marta Santisteban, Sara López‐Tarruella	10
9	Long-Lasting Response after Pembrolizumab in a Patient with Metastatic Triple-Negative Breast Cancer 2019 ·Breast Care ·(unknown), C. Ramírez, José Á. García-Sáenz, Alejandro Pascual, Jesús Fuentes‐Antrás, (unknown), (unknown), Fernando Moreno	1
10	Ethical and Legal Considerations in End-of-Life Care 2019 ·Primary Care Clinics in Office Practice ·(unknown), Fernando Moreno	7
11	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer 2016 ·Breast Cancer Research and Treatment ·Isabel Echavarría, (unknown), Coralia Bueno, Sara López‐Tarruella, (unknown), Miguel J. Sotelo, Yolanda Jerez, Fernando Moreno, (unknown), (unknown), Iván Márquez‐Rodas, Marı́a del Monte-Millán, Miguel Martín, José Á. García-Sáenz	11
12	Papel pronóstico del volumen metabólico tumoral y de la glucólisis tumoral total en los estudios 18F-FDG PET/TC de estadificación del cáncer localmente avanzado de mama 2016 ·Revista Española de Medicina Nuclear e Imagen Molecular ·(unknown), (unknown), (unknown), (unknown), José Á. García-Sáenz, (unknown), Manuel Fuentes, (unknown), (unknown), Fernando Moreno, J.L. Carreras-Delgado	7
13	Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study 2016 ·European Journal of Cancer ·Antonio Llombart‐Cussac, Manuel Ramos, E. Dalmau, José Á. García-Sáenz, Xavier González, Laura Murillo, Lourdes Calvo, Serafín Morales, Vicente Carañana, (unknown), (unknown), Fernando Moreno, (unknown), (unknown), (unknown), (unknown), Eva Carrasco, Carlos Jara-Sánchez	6
14	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial 2016 ·Breast Cancer Research and Treatment ·Milagros González‐Rivera, (unknown), Sara López‐Tarruella, Yolanda Jerez, Marı́a del Monte-Millán, Tatiana Massarrah, Rocío Ramos‐Medina, I Ocaña, Antoni C. Picornell, (unknown), Lucía Pérez‐Cabornero, José Á. García-Sáenz, Henry Gómez, Fernando Moreno, Iván Márquez‐Rodas, Hugo Fuentes, Miguel Martín	22
15	Efficacy and learning curve of a hand-held echocardiography device in an oncology outpatient clinic: Expanding the use of echoscopic heart examination beyond cardiology 2015 ·Molecular and Clinical Oncology ·(unknown), Fernando Moreno, (unknown), (unknown), Nuno Moreno, Carlos Aguado, José Agustín, (unknown), Miguel Ángel Cobos, Adriana Saltijeral, Carlos Macaya, Miguel Ángel García Fernández	5
16	Diseños de Abraham van Diepenbeeck para "Les peintures sacrées du Temple du Carmel" 2013 ·Fernando Moreno	1
17	El crucero de la catedral de Córdoba. Estudio iconográfico e iconológico 2007 ·Fernando Moreno	1
18	La visión emblemática del gobernante virtuoso 1985 ·Goya: Revista de arte ·Fernando Moreno	2
19	Estructura simbólica del túmulo de Isabel de Borbón en la Capilla Real de Granada 1979 ·Boletín del Seminario de Estudios de Arte y Arqueología: BSAA ·Fernando Moreno	0
20	The treatment of infectiousasthma in children with gamma globulin 1963 ·The Journal of Pediatrics ·Vincent J. Fontana, Ann G. Kuttner, Heinz J. Wittig, Fernando Moreno	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact